Virus-CKB (viral-associated disease-specific chemogenomics knowledgebase) is a bioinformatics platform developed to accelerate COVID-19 drug repurposing by predicting existing FDA-approved drugs that can undergo clinical trials. Traditional drug discovery can take up to 8 years, cost up to $2 billion, and suffer from low approval rates. Virus-CKB streamlines this process by facilitating viral infection research and identifying candidate therapeutics efficiently.